PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
121.05%
Net income growth of 121.05% while Biotechnology median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
473.10%
D&A growth of 473.10% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
20.60%
Deferred tax growth of 20.60% while Biotechnology median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-20.60%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
534.15%
Working capital of 534.15% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.02%
AP growth of 82.02% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
107.35%
Growth of 107.35% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-145.76%
Other non-cash items dropping yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-3.22%
Negative CFO growth while Biotechnology median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-7359.68%
CapEx declines yoy while Biotechnology median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-7359.68%
Reduced investing yoy while Biotechnology median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
37.62%
Debt repayment growth of 37.62% while Biotechnology median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
299.00%
Issuance growth of 299.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.